Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: The TRANSCEND study

Diabetes Care

Volumn 34, Issue 9, 2011, Pages 1902-1907

  Barzilay, Joshua I ^a   Gao, Peggy ^b   Rydén, Lars ^c   Schumacher, Helmut ^d   Probstfield, Jeffrey ^e   Commerford, Patrick ^f   Dans, Antonio ^g   Ferreira, Rafael ^h   Keltai, Mátyás ⁱ   Paolasso, Ernesto ^j   Yusuf, Salim ^b   Teo, Koon ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g PHILIPPINE GENERAL HOSPITAL   (Philippines)

^h Praceta Do Comercio   (Portugal)

ⁱ SEMMELWEIS UNIVERSITY   (Hungary)

^j Instituto Cardiovascular de Rosario   (Argentina)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PLACEBO; TELMISARTAN; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK ASSESSMENT; SINGLE BLIND PROCEDURE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIET RESTRICTION; DRUG EFFECT; GLUCOSE INTOLERANCE; MIDDLE AGED;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FASTING; FEMALE; GLUCOSE INTOLERANCE; HUMANS; MALE; MIDDLE AGED;

EID: 84856784851     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0545     Document Type: Article

References (17)

1. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201-207 (Pubitemid 46111014)
2. Yusuf S, Gerstein H, Hoogwerf B, et al.; HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 2001; 286:1882-1885 (Pubitemid 33010241)
3. Holman RR, Haffner SM, McMurray JJ, et al.; NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463-1476
4. Bosch J, Yusuf S, Gerstein HC, et al.; DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-1562 (Pubitemid 44550032)
5. TeoK, Yusuf S, Sleight P, et al.; ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;148:52-61 (Pubitemid 38906646)
6. Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005;4:6
7. Yamana A, Arita M, Furuta M, Shimajiri Y, Sanke T. The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control. Diabetes Res Clin Pract 2008;82:127-131
8. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342:905-912 (Pubitemid 30177050)
9. DeFronzo RA. The Claude Bernard Lecture 2009: Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. Diabetologia 2010;53:1270-1287
10. Dominguez LJ, Barbagallo M. The cardiometabolic syndrome and sarcopenic obesity in older persons. J Cardiometab Syndr 2007;2:183-189
11. Bhopal RS, Rafnsson SB. Could mitochondrial efficiency explain the susceptibility to adiposity, metabolic syndrome, diabetes and cardiovascular diseases in South Asian populations? Int J Epidemiol 2009;38:1072-1081
12. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005;23:463-473 (Pubitemid 40684700)
13. Norhammar A, Tenerz Å, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-2144 (Pubitemid 34694020)
14. Bartnik M, Rydén L, Ferrari R, et al.; Euro Heart Survey Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. Eur Heart J 2004;25:1880-1890 (Pubitemid 39452604)
15. Hsueh W, Davidai G, Henry R, Mudaliar S. Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension. J Clin Hypertens (Greenwich) 2010;12:746-752
16. Bokhari S, Israelian Z, Schmidt J, Brinton E, Meyer C. Effects of angiotensin II type 1 receptor blockade on β-cell function in humans. Diabetes Care 2007;30:181 (Pubitemid 46052522)
17. Paulweber B, Valensi P, Lindström J, et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res 2010;42(Suppl. 1): S3-S36